Antimicrobial ResistanceNews - Page 1

How diabetes fuels antibiotic resistance: What you need to know

Discover how diabetes accelerates antibiotic resistance, increasing the risk of untreatable infections. Find out more.

From Disease X to pandemics: The urgent need for new solutions

Richard Stead, CEO of Qures Group, explores the rise of pandemics and the ongoing battle against infectious diseases.

New FimCH vaccine shows promise in preventing recurrent urinary tract infections

Sequoia Vaccines’ FimCH vaccine oprevents recurrent UTIs by targeting bacterial adhesion, reducing infection recurrence, and addressing AMR.

UK publishes antimicrobial stewardship tool for effective treatment

The updated antimicrobial stewardship tool supports healthcare professionals in prescribing the most appropriate antibiotics for patients.

Oral antibodies for prophylactic treatment of enteric infectious diseases

Learn how Immuron is developing innovative colostrum-based oral antibodies to treat infectious diseases without the use of antibiotics.

Researchers discover breakthrough in the fight against VRE infections

Researchers have discovered a promising new compound, V-161, which effectively inhibits the growth of VRE infections.

From wastewater to wound care: How phages are found, harvested, and used

Discover how bacteriophages are sourced, refined, and used in cutting-edge treatments to combat infections and AMR.

How phage therapy can combat the global AMR crisis

Discover how phage therapy offers a revolutionary, targeted solution to combat the global antimicrobial resistance crisis.

How AI platforms can help us understand ABR and the POSTABR® era

Richard Stead, CEO of The Qures Group, discusses how different AI platforms can help us define different eras of antimicrobial resistance.

Dogs identified as spreaders of antimicrobial-resistant Salmonella

Discover more about the spread of and approaches needed to combat antimicrobial-resistant Salmonella in household dogs.

Global phage therapy market to reach $116m by 2028 amid rising AMR

Discover how the phage therapy market, valued at $116.6m by 2028, is revolutionising healthcare by addressing antibiotic resistance.

How the Global AMR Innovation Fund is leading the fight against antimicrobial resistance

Discover how the Global AMR Innovation Fund is combating antimicrobial resistance through innovation, global partnerships, and solutions.

Exeter launches second round of funding to tackle antifungal drug resistance

The FAILSAFE project is a groundbreaking initiative tackling antifungal drug resistance. Learn more about the project here.

Antibiotic resistance: 100 years of history

QURES Group offers a nature-inspired approach to effectively combat antibiotic resistance. Find out more now.

Innovation News Network - Free Digital eBook Library

Innovation News Network - Global Innovation Partners

Special Reports

Partner News

Special Reports Cont'd

Partner News Cont'd